Figure 1. Incidence chemotherapy-induced early- and late-phase nausea and vomiting was compared between patients who received highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) (A), as well as between patients who, besides HEC, received double antiemetic regimens (5HT3 receptor antagonist and dexamethasone) and triple antiemetic regimens (5HT3 receptor antagonist, dexamethasone, and aprepitant) (B).
